Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats

Vito De Gennaro Colonna, Sara Bonomo, Paolo Ferrario, Mauro Bianchi, Marco Berti, Marco Guazzi, Barbara Manfredi, Eugenio E. Muller, Ferruccio Berti, Giuseppe Rossoni

Research output: Contribution to journalArticle

Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) inhibitor recognized as an independent risk factor for endothelial dysfunction and coronary heart diseases. This study investigated whether ADMA (10 mg/kg day for 14 days) affected endothelial function and aggravated post-ischemic ventricular dysfunction in the perfused rat heart. Systolic blood pressure and heart rate, plasma levels of ADMA and nitrite/nitrate were measured in vehicle- and ADMA-treated rats. Perfused hearts were submitted to global ischemia-reperfusion and vascular endothelial dysfunction was examined with angiotensin II in coronary vessels and aortic rings. Endothelial NO synthase (eNOS) and angiotensin-converting enzyme (ACE) mRNA expression in aortic and cardiac tissues were measured. ADMA-treated rats had higher systolic blood pressure (1.3-fold, P <0.01) and slower heart rate (16%, P <0.05) than controls. Plasma ADMA rose (1.9-fold, P <0.01) and nitrite/nitrate concentration decreased 59% (P <0.001). Ventricular contraction (stiffness) increased significantly, with worsening of post-ischemic ventricular dysfunction. In preparations from ADMA-treated rats the coronary vasculature's response to angiotensin II was almost doubled (P <0.01) and the maximal vasorelaxant effect of acetylcholine in aortic rings was significantly lower than in preparations from vehicle-treated rats. In cardiac and aortic tissues eNOS mRNA and ACE mRNA levels were similar in controls and ADMA-treated rats. The increased plasma levels of ADMA presumably cause endothelial dysfunction because of a deficiency in NO production, which also appears involved in the aggravation of myocardial ischemia-reperfusion injury.

Original languageEnglish
Pages (from-to)178-185
Number of pages8
JournalEuropean Journal of Pharmacology
Volume557
Issue number2-3
DOIs
Publication statusPublished - Feb 28 2007

Fingerprint

Ventricular Dysfunction
Vascular Endothelium
Peptidyl-Dipeptidase A
Nitrites
Blood Pressure
Angiotensin II
Nitrates
Messenger RNA
Nitric Oxide
Heart Rate
Myocardial Reperfusion Injury
N,N-dimethylarginine
Nitric Oxide Synthase Type III
Reperfusion Injury
Vasodilator Agents
Nitric Oxide Synthase
Acetylcholine
Reperfusion
Myocardial Ischemia
Coronary Disease

Keywords

  • (Rat)
  • Asymmetric dimethylarginine
  • Endothelial dysfunction
  • Myocardial ischemia-reperfusion

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. / De Gennaro Colonna, Vito; Bonomo, Sara; Ferrario, Paolo; Bianchi, Mauro; Berti, Marco; Guazzi, Marco; Manfredi, Barbara; Muller, Eugenio E.; Berti, Ferruccio; Rossoni, Giuseppe.

In: European Journal of Pharmacology, Vol. 557, No. 2-3, 28.02.2007, p. 178-185.

Research output: Contribution to journalArticle

De Gennaro Colonna, V, Bonomo, S, Ferrario, P, Bianchi, M, Berti, M, Guazzi, M, Manfredi, B, Muller, EE, Berti, F & Rossoni, G 2007, 'Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats', European Journal of Pharmacology, vol. 557, no. 2-3, pp. 178-185. https://doi.org/10.1016/j.ejphar.2006.11.034
De Gennaro Colonna, Vito ; Bonomo, Sara ; Ferrario, Paolo ; Bianchi, Mauro ; Berti, Marco ; Guazzi, Marco ; Manfredi, Barbara ; Muller, Eugenio E. ; Berti, Ferruccio ; Rossoni, Giuseppe. / Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats. In: European Journal of Pharmacology. 2007 ; Vol. 557, No. 2-3. pp. 178-185.
@article{49ff23a21bd14fd6b3c3024e99612cf3,
title = "Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats",
abstract = "Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) inhibitor recognized as an independent risk factor for endothelial dysfunction and coronary heart diseases. This study investigated whether ADMA (10 mg/kg day for 14 days) affected endothelial function and aggravated post-ischemic ventricular dysfunction in the perfused rat heart. Systolic blood pressure and heart rate, plasma levels of ADMA and nitrite/nitrate were measured in vehicle- and ADMA-treated rats. Perfused hearts were submitted to global ischemia-reperfusion and vascular endothelial dysfunction was examined with angiotensin II in coronary vessels and aortic rings. Endothelial NO synthase (eNOS) and angiotensin-converting enzyme (ACE) mRNA expression in aortic and cardiac tissues were measured. ADMA-treated rats had higher systolic blood pressure (1.3-fold, P <0.01) and slower heart rate (16{\%}, P <0.05) than controls. Plasma ADMA rose (1.9-fold, P <0.01) and nitrite/nitrate concentration decreased 59{\%} (P <0.001). Ventricular contraction (stiffness) increased significantly, with worsening of post-ischemic ventricular dysfunction. In preparations from ADMA-treated rats the coronary vasculature's response to angiotensin II was almost doubled (P <0.01) and the maximal vasorelaxant effect of acetylcholine in aortic rings was significantly lower than in preparations from vehicle-treated rats. In cardiac and aortic tissues eNOS mRNA and ACE mRNA levels were similar in controls and ADMA-treated rats. The increased plasma levels of ADMA presumably cause endothelial dysfunction because of a deficiency in NO production, which also appears involved in the aggravation of myocardial ischemia-reperfusion injury.",
keywords = "(Rat), Asymmetric dimethylarginine, Endothelial dysfunction, Myocardial ischemia-reperfusion",
author = "{De Gennaro Colonna}, Vito and Sara Bonomo and Paolo Ferrario and Mauro Bianchi and Marco Berti and Marco Guazzi and Barbara Manfredi and Muller, {Eugenio E.} and Ferruccio Berti and Giuseppe Rossoni",
year = "2007",
month = "2",
day = "28",
doi = "10.1016/j.ejphar.2006.11.034",
language = "English",
volume = "557",
pages = "178--185",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Asymmetric dimethylarginine (ADMA) induces vascular endothelium impairment and aggravates post-ischemic ventricular dysfunction in rats

AU - De Gennaro Colonna, Vito

AU - Bonomo, Sara

AU - Ferrario, Paolo

AU - Bianchi, Mauro

AU - Berti, Marco

AU - Guazzi, Marco

AU - Manfredi, Barbara

AU - Muller, Eugenio E.

AU - Berti, Ferruccio

AU - Rossoni, Giuseppe

PY - 2007/2/28

Y1 - 2007/2/28

N2 - Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) inhibitor recognized as an independent risk factor for endothelial dysfunction and coronary heart diseases. This study investigated whether ADMA (10 mg/kg day for 14 days) affected endothelial function and aggravated post-ischemic ventricular dysfunction in the perfused rat heart. Systolic blood pressure and heart rate, plasma levels of ADMA and nitrite/nitrate were measured in vehicle- and ADMA-treated rats. Perfused hearts were submitted to global ischemia-reperfusion and vascular endothelial dysfunction was examined with angiotensin II in coronary vessels and aortic rings. Endothelial NO synthase (eNOS) and angiotensin-converting enzyme (ACE) mRNA expression in aortic and cardiac tissues were measured. ADMA-treated rats had higher systolic blood pressure (1.3-fold, P <0.01) and slower heart rate (16%, P <0.05) than controls. Plasma ADMA rose (1.9-fold, P <0.01) and nitrite/nitrate concentration decreased 59% (P <0.001). Ventricular contraction (stiffness) increased significantly, with worsening of post-ischemic ventricular dysfunction. In preparations from ADMA-treated rats the coronary vasculature's response to angiotensin II was almost doubled (P <0.01) and the maximal vasorelaxant effect of acetylcholine in aortic rings was significantly lower than in preparations from vehicle-treated rats. In cardiac and aortic tissues eNOS mRNA and ACE mRNA levels were similar in controls and ADMA-treated rats. The increased plasma levels of ADMA presumably cause endothelial dysfunction because of a deficiency in NO production, which also appears involved in the aggravation of myocardial ischemia-reperfusion injury.

AB - Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide (NO) inhibitor recognized as an independent risk factor for endothelial dysfunction and coronary heart diseases. This study investigated whether ADMA (10 mg/kg day for 14 days) affected endothelial function and aggravated post-ischemic ventricular dysfunction in the perfused rat heart. Systolic blood pressure and heart rate, plasma levels of ADMA and nitrite/nitrate were measured in vehicle- and ADMA-treated rats. Perfused hearts were submitted to global ischemia-reperfusion and vascular endothelial dysfunction was examined with angiotensin II in coronary vessels and aortic rings. Endothelial NO synthase (eNOS) and angiotensin-converting enzyme (ACE) mRNA expression in aortic and cardiac tissues were measured. ADMA-treated rats had higher systolic blood pressure (1.3-fold, P <0.01) and slower heart rate (16%, P <0.05) than controls. Plasma ADMA rose (1.9-fold, P <0.01) and nitrite/nitrate concentration decreased 59% (P <0.001). Ventricular contraction (stiffness) increased significantly, with worsening of post-ischemic ventricular dysfunction. In preparations from ADMA-treated rats the coronary vasculature's response to angiotensin II was almost doubled (P <0.01) and the maximal vasorelaxant effect of acetylcholine in aortic rings was significantly lower than in preparations from vehicle-treated rats. In cardiac and aortic tissues eNOS mRNA and ACE mRNA levels were similar in controls and ADMA-treated rats. The increased plasma levels of ADMA presumably cause endothelial dysfunction because of a deficiency in NO production, which also appears involved in the aggravation of myocardial ischemia-reperfusion injury.

KW - (Rat)

KW - Asymmetric dimethylarginine

KW - Endothelial dysfunction

KW - Myocardial ischemia-reperfusion

UR - http://www.scopus.com/inward/record.url?scp=33846580547&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846580547&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2006.11.034

DO - 10.1016/j.ejphar.2006.11.034

M3 - Article

C2 - 17258196

AN - SCOPUS:33846580547

VL - 557

SP - 178

EP - 185

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -